Achieve Life Science Inc. (ACHV)

[SuperDrive]

Up to date status:

Short DD overview for potential investors:

Market cap:
$34M


Cash on hand:
$22M


Oustanding shares after offering: 3.2M shares

Starting a Phase 3 in the US for a drug called cytisinicline that helps smokers quit.

Drug is already used for years in Europe (20 million people have used it there).

Other competitor already in the Market is Chantrix, its market is about $1.2B.

ACHV just registered a patent related to this drug and is about to launch a Phase 3 by years end. Given the extensive use in Europe, Approval is almost guaranteed.

Here under you'll find a link to an article related to a Phase 3 trial for cytisinicline in New-Zealand showing non-inferiority to Chantrix and lower side effects.

https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2020/ACHV-RAUORA-Cytisiniclines-Superior-Side-Effect-Profile/default.aspx

Results of New-Zealand Phase 3 trials to be officially presented in september.

If they get just 15% of Chantrix market, with a p/s ratio of only 1, MC -->
$180M

--> a 5 bagger for a drug already heavily used in Europe.